Inclusion Criteria:

          1. Patients aged >= 20 years at informed consent.

          2. Patients who have provided written informed consent themselves.

          3. Patients who have metastatic and/or advanced lesion

          4. Documentation of ER-positive and/or PR-positive tumor (>=1% positive stained cells).

          5. Patients with cancer confirmed to be HER2-negative.

          6. Patients with confirmed menopause

          7. Patients who have plans of 2nd hormone therapy.

          8. Patients with a measurable lesion based on RECIST 1.1

          9. Patients with ECOG PS of 0 to 1.

         10. Patients without any severe disorder in the major organs.

        Exclusion Criteria:

        -

        Exclusion Criteria:

          1. Active or prior documented autoimmune disease within the past 2 years.

          2. Current or prior use of immunosuppressive medication within 28 days before the first
             dose of durvalumab or tremelimumab

          3. Patients with central nervous system metastasis

          4. Patients with life-threatening disease.

          5. Patients with a history of treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 or
             anti-CTLA-4 antibody drug.

          6. Patients who have received live vaccination within 30 days before start of the
             investigational products.

          7. Patients with a past medical history of pneumonia requiring steroid treatment or with
             a past medical history of interstitial pneumonia.

          8. Patients considered ineligible for participation in this study by their attending
             physicians.